Anticipate generic drug launch
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
DrugPatentWatch was founded in 2002 in response to repeated requests for a streamlined resource for drug patent expiration dates.
While the original focus was on the United States market, DrugPatentWatch now includes global patents in over 100 countries, and even expired patents dating back decades.
In response to customer feedback over the years DrugPatentWatch has continued to expand its offerings, and datasets have been added for formulations, suppliers, clinical trials. Today the uses cases have expanded and include healthcare payers, branded and generic manufactuters, and wholesalers and distributors.
Use cases for the database include:
Different plans are available to meet your specific needs.
DrugPatentWatch incorporates data directly from the FDA, Patent and Trademark Office, and other US and foreign government sources. Each is updated as frequently as possible — often daily — providing you with fresh information.
For those seeking information on now-expired patents, annual editions provide historic archives dating back to the Hatch-Waxman Act — arguably for as long as generic drugs have existed.
DrugPatentWatch contains information on FDA-approved small molecule drugs. For information on biologics see DrugPatentWatch's sister site, BiologicPatentWatch.com
While DrugPatentWatch includes information on expired patents, archived copies of the FDA Orange Book in PDF format are also available in the Orange Book Archives.
DrugPatentWatch is developed by Yali Friedman, Ph.D.
Dr. Friedman is also publisher of the Journal of Commercial Biotechnology and author of Building Biotechnology, which is used as a course text in dozens of biotechnology programs. He also serves as head of data analytics for Scientific American Custom Media, and was also named one of the 100 most influential people in biotechnology by Scientific American.
Dr. Friedman has strong exposure to leading issues in international biotechnology. He is editor of the Scientific American worldVIEW scorecard, a global biotechnology perspective profiling biotechnology industries and innovation capacity in dozens of countries, and has been invited to participate in biotechnology industry development forums for international groups such as APEC, in Europe, and throughout Asia.
Do you have needs beyond DrugPatentWatch's current offerings? Please contact us.